Angiogenesis Inhibitors in Small Cell Lung Cancer

Inhibition of angiogenesis has been demonstrated to be an efficacious strategy in treating several tumors. Vascular endothelial growth factor (VEGF) is the most important protein with proangiogenic functions and it is overexpressed in small cell lung cancer (SCLC). Bevacizumab, a monoclonal antibody directed against VEGF, showed a promising activity in combination with etoposide and cisplatin as first-line treatment of patients with extended stage (ES)-SCLC and two randomized studies confirmed that bevacizumab improved PFS, but failed to prolong OS. Instead, disappointing results have been observed with endostar, sunitinib, sorafenib, vandetanib, and thalidomide in combination with chemotherapy in the first-line setting, with sunitinib in the maintenance setting, with sunitinib, cediranib and nintedanib as single agents or ziv-aflibercept in combination with topotecan in second-line setting. Only anlotinib improved OS and PFS as third-line therapy in Chinese patients with SCLC, and it was approved with this indication in China. Future challenges are the evaluation of the role of angiogenesis inhibitors in combination with immune- checkpoint inhibitors and chemotherapy in SCLC patients and the identification of predictive biomarkers of response to both agents.

[1]  Lifeng Wang,et al.  Camrelizumab Plus Apatinib in Extensive-Stage Small-Cell Lung Cancer (PASSION): A Multicenter, Two-Stage, Phase 2 Trial. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  Qin Li,et al.  Efficacy and Safety of Anlotinib for Elderly Patients with Previously Treated Extensive-Stage SCLC and the Prognostic Significance of Common Adverse Reactions , 2020, Cancer management and research.

[3]  G. Botti,et al.  Immunotherapy in Small Cell Lung Cancer , 2020, Cancers.

[4]  W. Fang,et al.  Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study. , 2020 .

[5]  Peng Liu,et al.  A Prospective Study of Apatinib in Patients with Extensive‐Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy , 2020, The oncologist.

[6]  S. Peters,et al.  Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. , 2020, The Lancet. Oncology.

[7]  R. Bianco,et al.  Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents , 2020, Journal of clinical medicine.

[8]  Bevacizumab , 2019, Reactions Weekly.

[9]  Yoon-Koo Kang,et al.  Randomized phase III ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens , 2019, Annals of Oncology.

[10]  Y. Liu,et al.  Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC) , 2019, Annals of Oncology.

[11]  Wenfeng Li,et al.  Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study , 2019, British Journal of Cancer.

[12]  FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma , 2019, Case Medical Research.

[13]  Ying Cheng,et al.  Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial , 2018, JAMA oncology.

[14]  A. Mansfield,et al.  First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[15]  M. Odenthal,et al.  Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer. , 2018, Cancer research.

[16]  Federico Cappuzzo,et al.  Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC , 2018, The New England journal of medicine.

[17]  R. Kerbel,et al.  Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa , 2018, Nature Reviews Clinical Oncology.

[18]  Xuan Liang,et al.  Angiogenesis inhibitors for the treatment of small cell lung cancer (SCLC) , 2017, Medicine.

[19]  C. Tibaldi,et al.  Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  N. Hanna,et al.  A randomized, double‐blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive‐stage small cell lung cancer: Hoosier Cancer Research Network LUN06‐113 , 2017, Cancer.

[21]  C. Sandomenico,et al.  Focus on Nintedanib in NSCLC and Other Tumors , 2016, Front. Med..

[22]  K. Lim,et al.  A phase II study of nintedanib in patients with relapsed small cell lung cancer. , 2016, Lung cancer.

[23]  E. Smit,et al.  Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061). , 2016, European journal of cancer.

[24]  N. Yang,et al.  Elevated Serum Level of Angiopoietin-2 as a Potential Marker for Poor Prognosis in Small Cell Lung Cancer. , 2015, The Tohoku journal of experimental medicine.

[25]  P. Lamy,et al.  Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  E. Vokes,et al.  Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Roman K. Thomas,et al.  PD-L1 expression in small cell neuroendocrine carcinomas. , 2015, European journal of cancer.

[28]  Baolan Li,et al.  A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  K. Kelly,et al.  Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Pujol,et al.  Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: Results from the IFCT-0802 trial. , 2014 .

[31]  A. D. Van den Abbeele,et al.  Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma , 2014, Cancer Immunology Research.

[32]  B. Halmos,et al.  Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer , 2014, Investigational New Drugs.

[33]  K. Lim,et al.  A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer. , 2013, Lung cancer.

[34]  J. Hainsworth,et al.  Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer. , 2012, Lung cancer.

[35]  N. Normanno,et al.  Bevacizumab in non small cell lung cancer: development, current status and issues. , 2012, Current medicinal chemistry.

[36]  E. Vokes,et al.  Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Wozniak,et al.  Phase II Trial of Sunitinib Maintenance Therapy After Platinum-Based Chemotherapy in Patients with Extensive-Stage Small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[38]  M. Socinski,et al.  Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  F. Zhou,et al.  Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer , 2011, Cancer Chemotherapy and Pharmacology.

[40]  R. Govindan,et al.  Phase II Study of Cediranib (AZD 2171), an Inhibitor of the Vascular Endothelial Growth Factor Receptor, for Second-Line Therapy of Small Cell Lung Cancer (National Cancer Institute #7097) , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[41]  D. Moore,et al.  Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  A. Hackshaw,et al.  Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. , 2009, Journal of the National Cancer Institute.

[43]  N. Normanno,et al.  Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. , 2009, The oncologist.

[44]  S. Lippman,et al.  Lung cancer. , 2008, The New England journal of medicine.

[45]  U. Ozbek,et al.  Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients , 2008, Medical oncology.

[46]  P. Ellis,et al.  Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer. , 2008, Lung cancer.

[47]  L. Seymour,et al.  Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  J. Hainsworth,et al.  Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[49]  J. Pujol,et al.  Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Michael R. Green,et al.  CALGB 30306: A phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC) , 2007 .

[51]  T. Mekhail,et al.  Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy. , 2007, Lung cancer.

[52]  N. Normanno,et al.  Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. , 2006, The oncologist.

[53]  Paolo Valerio,et al.  Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. , 2006, Current medicinal chemistry.

[54]  J. Hainsworth,et al.  Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by maintenance bevacizumab (B) in the treatment (tx) of limited-stage small cell lung cancer (LS-SCLC): Update of a phase II trial of the Minnie Pearl Cancer Research Network. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[56]  C. Angeletti,et al.  A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma , 2002, British Journal of Cancer.

[57]  G. Gasparini,et al.  Thalidomide: an old sedative-hypnotic with anticancer activity? , 2001, Current opinion in investigational drugs.

[58]  Leonard,et al.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.

[59]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[60]  D. Osoba,et al.  VP-16 and cisplatin as first-line therapy for small-cell lung cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  T. Jiang,et al.  OA11.07 Combining Anti-Angiogenesis and Immunotherapy Enhances Antitumor Effect by Promoting Immune Response in Lung Cancer , 2017 .

[62]  Stuart Moss,et al.  Current Status and Future Directions , 2013 .

[63]  N. Agnantis,et al.  Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in small-cell and non-small-cell lung carcinomas. , 2004, Histology and histopathology.

[64]  Thomas R. Riley,et al.  A Randomized Double-blind Placebo-controlled Trial , 2004 .

[65]  J. Mall,et al.  Long-term survival of a patient with small-cell lung cancer (SCLC) following treatment with thalidomide and combination chemotherapy , 2004, Angiogenesis.

[66]  J. Hainsworth,et al.  Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. , 2002, Cancer.